S
Sunita D. Nasta
Researcher at University of Pennsylvania
Publications - 185
Citations - 6397
Sunita D. Nasta is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Lymphoma & Transplantation. The author has an hindex of 31, co-authored 164 publications receiving 4979 citations. Previous affiliations of Sunita D. Nasta include Hospital of the University of Pennsylvania & Children's Hospital of Philadelphia.
Papers
More filters
Journal ArticleDOI
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster,Jakub Svoboda,Elise A. Chong,Sunita D. Nasta,Anthony R. Mato,Özlem Anak,Jennifer Brogdon,Iulian Pruteanu-Malinici,Vijay Bhoj,Daniel J. Landsburg,Mariusz A. Wasik,Bruce L. Levine,Simon F. Lacey,J. Joseph Melenhorst,David L. Porter,Carl H. June +15 more
TL;DR: CTL019 cells can be effective in the treatment of relapsed or refractory diffuse large B‐cell lymphoma and follicular lymphoma, and high rates of durable remission were observed, with recovery of B cells and immunoglobulins in some patients.
Journal ArticleDOI
International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease
David C. Fajgenbaum,Thomas S. Uldrick,Adam Bagg,Dale Frank,David Wu,Gordan Srkalovic,David Simpson,Amy Y. Liu,David M. Menke,Shanmuganathan Chandrakasan,Mary Jo Lechowicz,Raymond S.M. Wong,Sheila K Pierson,Michele Paessler,Jean François Rossi,Makoto Ide,Jason R. Ruth,Michael P. Croglio,Alexander Suarez,Vera P. Krymskaya,Amy Chadburn,Gisele W. B. Colleoni,Sunita D. Nasta,Raj Jayanthan,Christopher S. Nabel,Corey Casper,Angela Dispenzieri,Alexander Fosså,Dermot Kelleher,Razelle Kurzrock,Peter M. Voorhees,Ahmet Dogan,Kazuyuki Yoshizaki,Frits van Rhee,Eric Oksenhendler,Elaine S. Jaffe,Kojo S.J. Elenitoba-Johnson,Megan S. Lim +37 more
TL;DR: The proposed consensus criteria will facilitate consistent diagnosis, appropriate treatment, and collaborative research and exclude infectious, malignant, and autoimmune disorders that can mimic iMCD.
Journal ArticleDOI
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
Andre Goy,Steven H. Bernstein,Brad S. Kahl,Benjamin Djulbegovic,Michael J. Robertson,S. de Vos,Elliot M. Epner,Amrita Krishnan,John P. Leonard,Sagar Lonial,Sunita D. Nasta,Owen A. O'Connor,Hongliang Shi,Anthony Boral,Richard I. Fisher +14 more
TL;DR: Single-agent bortezomib is associated with lengthy responses and notable survival in patients with relapsed or refractory MCL, with considerable TTP and TTNT in responding patients, suggesting substantial clinical benefit.
Journal ArticleDOI
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato,Chadhi Nabhan,Meghan C. Thompson,Nicole Lamanna,Danielle M. Brander,Brian T. Hill,Christina Howlett,Alan P Skarbnik,Bruce D. Cheson,Clive S. Zent,Jeffrey Pu,Pavel Kiselev,Andre Goy,David F. Claxton,Krista Isaac,Kaitlin Kennard,Colleen Timlin,Daniel J. Landsburg,Allison M. Winter,Sunita D. Nasta,Spencer Henick Bachow,Stephen J. Schuster,Colleen Dorsey,Jakub Svoboda,Paul M. Barr,Chaitra S. Ujjani +25 more
TL;DR: In the largest reported series on ibrutinib- treated chronic lymphocytic leukemia patients, it is shown that 41% of patients discontinued ibrUTinib, the most common reason for discontinuation in all settings.
Journal ArticleDOI
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Anjali S. Advani,Bertrand Coiffier,Myron S. Czuczman,Martin Dreyling,James M. Foran,Eva Giné,Christian Gisselbrecht,Nicolas Ketterer,Sunita D. Nasta,Ama Z. S. Rohatiner,Ingo G.H. Schmidt-Wolf,Martin Schuler,Jorge Sierra,Mitchell R. Smith,Gregor Verhoef,Jane N. Winter,Joseph Boni,Erik Vandendries,Mark Shapiro,Luis Fayad +19 more
TL;DR: Inotuzumab ozogamicin has demonstrated efficacy against CD22(+) B-cell NHL, with reversible thrombocytopenia as the main toxicity.